Jupiter Topco LLC Purchases Shares of 20,686 IQVIA Holdings Inc. $IQV

Jupiter Topco LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,686 shares of the medical research company’s stock, valued at approximately $3,995,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter worth approximately $2,811,292,000. Boston Partners bought a new stake in shares of IQVIA in the 3rd quarter valued at $676,698,000. Norges Bank acquired a new stake in shares of IQVIA during the fourth quarter worth $497,445,000. Victory Capital Management Inc. raised its stake in IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after buying an additional 1,614,063 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in IQVIA in the second quarter valued at $240,911,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a report on Thursday, July 9th. BMO Capital Markets upped their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Robert W. Baird raised their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Finally, HSBC restated a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Stock Performance

Shares of IQV opened at $258.39 on Wednesday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $265.25. The company has a market cap of $42.53 billion, a PE ratio of 32.06, a P/E/G ratio of 2.23 and a beta of 1.18. The stock has a 50-day moving average of $225.75 and a 200-day moving average of $190.73. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at IQVIA

In other news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 over the last ninety days. 1.70% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.